The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review
Open accessAbstract
Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid arthritis (RA). It was developed in 2008, and its effectiveness is supported by evidence from all over the world based on its first decade of use. Although the overall efficacy and safety profiles of TCZ are similar to those of tumor necrosis factor (TNF) inhibitors, TCZ displays certain differences. The most notable advantage of TCZ is its usefulness as a monotherapy. Additionally, TCZ is favorable in the improvement of systemic inflammatory symptoms such as anemia and fatigue. The low immunogenicity of TCZ contributes favorably to long-term drug retention. Due to frequent relapse after TCZ cessation, TCZ use should be tapered beyond remission. During TCZ therapy, C-reactive protein (CRP) is unable to recognize disease activity and the severity of infection. The most common adverse events (AEs) are infection and abnormalities in laboratory findings including dyslipidemia, neutropenia, thrombocytopenia, and abnormality of liver enzymes. TCZ obscures the symptoms of infection. Therefore, stealth infections without obvious CRP elevation can sometimes cause severe damage to patients. Lower intestinal perforation is an uncommon but serious AE in TCZ therapy. Further clinical investigations will continue to refine the IL-6 inhibitory strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 1×
“Although IL-6 plays important roles in reproductive performance, embryonal development, parturition, and postnatal development, IL-6 signal blockade with a rat antimouse IL-6 receptor antibody (MR16-1) and IL-6-deficient mice revealed no biologically important effects on fertility, embryonic implantation, or prenatal/…”
BackgroundGenovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855
Houssiau, F. A., Devogelaer, J., Damme, J. V., Deuxchaisnes, C. N. D., & Snick, J. V. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310614 · Cited by 847
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
Kaser, A., Brandacher, G., Steurer, W., Kaser, S., Offner, F. A., Zoller, H., Theurl, I., Widder, W., Molnar, C., Ludwiczek, O., et al. (2001) · Blood · doi:10.1182/blood.v98.9.2720 · Cited by 667
The role of interleukins in insulin resistance and type 2 diabetes mellitus
Fève, B., & Bastard, J.-P. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.62 · Cited by 343
Role of interleukin-6 in stress, sleep, and fatigue
Rohleder, N., Aringer, M., & Boentert, M. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06634.x · Cited by 289
Interleukin 6 and liver regeneration
STREETZ, K. L., LUEDDE, T., MANNS, M. P., & TRAUTWEIN, C. (2000) · Gut · doi:10.1136/gut.47.2.309 · Cited by 238
Song, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood · doi:10.1182/blood-2010-03-271791 · Cited by 228
Self-citationMonocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
Singh, N., Hofmann, T. J., Gershenson, Z., Levine, B. L., Grupp, S. A., Teachey, D. T., & Barrett, D. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.04.001 · Cited by 151
Cited by
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
Capra, R., De Rossi, N., Mattioli, F., Romanelli, G., Scarpazza, C., Sormani, M. P., & Cossi, S. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.009 · Cited by 271
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Copaescu, A., Smibert, O., Gibson, A., Phillips, E. J., & Trubiano, J. A. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.001 · Cited by 262
Senescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
Metadata
- Authors
- Ogata, A., Kato, Y., Higa, S., & Yoshizaki, K.
- Venue
- Modern Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-03
- Volume
- 29
- Issue
- 2
- Pages
- 258-267
- ISSN
- 1439-7595 (ISSN-L)
- 1439-7609
- OpenAlex
- W2901098088
- Cited by
- 211
- References
- 10
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. https://app.cochat.ai/papers/10.1080/14397595.2018.1546357
- The paper
- Ogata, A., Kato, Y., Higa, S., & Yoshizaki, K. (2019). IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology. https://doi.org/10.1080/14397595.2018.1546357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.